EUVIMEDEUVIMED entdecken
Open Access

Heterologous prime-boost vaccination drives early maturation of HIV broadly neutralizing antibody precursors in humanized mice

Christopher A Cottrell iD, Xiaozhen Hu iD, Jeong Hyun Lee iD, Patrick Skog iD, Sai Luo iD, Claudia T Flynn, Katherine R McKenney, Jonathan Hurtado iD, Oleksandr Kalyuzhniy iD, Alessia Liguori iD, Jordan R Willis iD, Elise Landais iD und 25 weitere

Science Translational Medicine · 22.05.2024 · 16 (748)

DOI: 10.1126/scitranslmed.adn0223 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Science Translational Medicine, erschienen am 22.05.2024. Verfasst von Christopher A Cottrell und 36 weiteren Autor:innen. Beteiligte Einrichtung: Department of Immunology and Microbial Science, Scripps Research Institute, La Jolla, CA 92037, USA. Hauptthemen laut MEDLINE: AIDS Vaccines, Antibodies, Neutralizing, HIV Antibodies. Die Arbeit wurde bisher 78-mal zitiert (Crossref) und nennt 72 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

A protective HIV vaccine will likely need to induce broadly neutralizing antibodies (bnAbs). Vaccination with the germline-targeting immunogen eOD-GT8 60mer adjuvanted with AS01 B was found to induce VRC01-class bnAb precursors in 97% of vaccine recipients in the IAVI G001 phase 1 clinical trial; however, heterologous boost immunizations with antigens more similar to the native glycoprotein will be required to induce bnAbs. Therefore, we designed core-g28v2 60mer, a nanoparticle immunogen to be used as a first boost after eOD-GT8 60mer priming. We found, using a humanized mouse model approximating human conditions of VRC01-class precursor B cell diversity, affinity, and frequency, that both protein- and mRNA-based heterologous prime-boost regimens induced VRC01-class antibodies that gained key mutations and bound to near-native HIV envelope trimers lacking the N276 glycan. We further showed that VRC01-class antibodies induced by mRNA-based regimens could neutralize pseudoviruses lacking the N276 glycan. These results demonstrated that heterologous boosting can drive maturation toward VRC01-class bnAb development and supported the initiation of the IAVI G002 phase 1 trial testing mRNA-encoded nanoparticle prime-boost regimens.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AIDS VaccinesAntibodies, NeutralizingHIV AntibodiesAnimalsHumansMiceVaccinationImmunization, SecondaryHIV-1HIV InfectionsBroadly Neutralizing Antibodies

Substanzen

AIDS VaccinesAntibodies, NeutralizingHIV AntibodiesBroadly Neutralizing Antibodies

Autor:innen und Institutionen

  • Department of Immunology and Microbial Science, Scripps Research Institute, La Jolla, CA 92037, USA.
  • Center for HIV/AIDS Vaccine Development, Scripps Research Institute, La Jolla, CA 92037, USA.
  • IAVI Neutralizing Antibody Center, Scripps Research Institute, La Jolla, CA 92037, USA.
  • Moderna Therapeutics, Cambridge, MA 02139, USA.
  • HHMI, Boston Children's Hospital, Boston, MA 02115, USA.
  • Program in Cellular and Molecular Medicine, Boston Children's Hospital, Boston, MA 02115, USA.

ORCID-Profile: Christopher A Cottrell, Xiaozhen Hu, Jeong Hyun Lee, Patrick Skog, Sai Luo, Jonathan Hurtado, Oleksandr Kalyuzhniy, Alessia Liguori, Jordan R Willis, Elise Landais, Sebastian Raemisch, Xuejun Chen, Sabyasachi Baboo, Sunny Himansu, Jolene K Diedrich, Hongying Duan, Cheng Cheng, Daniel L V Bader, Daniel W Kulp, Ryan Tingle, Erik Georgeson, Saman Eskandarzadeh, Nushin Alavi, Danny Lu, Troy Sincomb, Tina-Marie Mullen, John R Yates, James C Paulson, John R Mascola, Frederick W Alt, Bryan Briney, Devin Sok, William R Schief

Förderung

  • NIAID NIH HHS

Zitieren

APA

Cottrell, C. A., Hu, X., Lee, J. H., Skog, P., Luo, S., Flynn, C. T., McKenney, K. R., Hurtado, J., Kalyuzhniy, O., Liguori, A., Willis, J. R., Landais, E., Raemisch, S., Chen, X., Baboo, S., Himansu, S., Diedrich, J. K., Duan, H., Cheng, C., …, & Schief, W. R. (2024). Heterologous prime-boost vaccination drives early maturation of HIV broadly neutralizing antibody precursors in humanized mice. Science Translational Medicine, 16(748). https://doi.org/10.1126/scitranslmed.adn0223

Vancouver

Cottrell CA, Hu X, Lee JH, Skog P, Luo S, Flynn CT, et al. Heterologous prime-boost vaccination drives early maturation of HIV broadly neutralizing antibody precursors in humanized mice. Science Translational Medicine. 2024;16(748). doi:10.1126/scitranslmed.adn0223

BibTeX
@article{Cottrell2024,
  author = {Cottrell, Christopher A and Hu, Xiaozhen and Lee, Jeong Hyun and Skog, Patrick and Luo, Sai and Flynn, Claudia T and McKenney, Katherine R and Hurtado, Jonathan and Kalyuzhniy, Oleksandr and Liguori, Alessia and Willis, Jordan R and Landais, Elise and Raemisch, Sebastian and Chen, Xuejun and Baboo, Sabyasachi and Himansu, Sunny and Diedrich, Jolene K and Duan, Hongying and Cheng, Cheng and Schiffner, Torben and Bader, Daniel L V and Kulp, Daniel W and Tingle, Ryan and Georgeson, Erik and Eskandarzadeh, Saman and Alavi, Nushin and Lu, Danny and Sincomb, Troy and Kubitz, Michael and Mullen, Tina-Marie and Yates, John R and Paulson, James C and Mascola, John R and Alt, Frederick W and Briney, Bryan and Sok, Devin and Schief, William R},
  title = {Heterologous prime-boost vaccination drives early maturation of HIV broadly neutralizing antibody precursors in humanized mice},
  journal = {Science Translational Medicine},
  year = {2024},
  volume = {16},
  number = {748},
  doi = {10.1126/scitranslmed.adn0223}
}
Kostenlos starten →